ProQR Therapeutics N.V.
PRQR
$1.63
$0.095.84%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 20.43M | 19.38M | 16.64M | 11.17M | 7.04M |
| Total Other Revenue | 692.60K | 547.60K | 395.90K | 269.40K | 86.40K |
| Total Revenue | 21.13M | 19.93M | 17.04M | 11.44M | 7.13M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 21.13M | 19.93M | 17.04M | 11.44M | 7.13M |
| SG&A Expenses | 14.77M | 15.71M | 15.71M | 16.98M | 17.55M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.09M | 52.05M | 47.63M | 47.74M | 44.73M |
| Operating Income | -32.97M | -32.13M | -30.59M | -36.30M | -37.61M |
| Income Before Tax | -30.26M | -26.23M | -23.26M | -28.88M | -30.07M |
| Income Tax Expenses | -212.00K | -206.60K | -251.20K | -81.60K | -84.90K |
| Earnings from Continuing Operations | -30.04 | -26.03 | -23.01 | -28.80 | -29.98 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | 0.00 | -315.60K | -333.00K | -416.60K |
| Net Income | -30.04M | -26.03M | -23.33M | -29.13M | -30.40M |
| EBIT | -32.97M | -32.13M | -30.59M | -36.30M | -37.61M |
| EBITDA | -30.46M | -29.67M | -28.19M | -34.03M | -35.49M |
| EPS Basic | -0.35 | -0.32 | -0.29 | -0.36 | -0.38 |
| Normalized Basic EPS | -0.22 | -0.23 | -0.22 | -0.26 | -0.28 |
| EPS Diluted | -0.35 | -0.32 | -0.29 | -0.36 | -0.38 |
| Normalized Diluted EPS | -0.22 | -0.23 | -0.22 | -0.26 | -0.28 |
| Average Basic Shares Outstanding | 344.35M | 326.14M | 325.45M | 324.73M | 324.04M |
| Average Diluted Shares Outstanding | 344.35M | 326.14M | 325.45M | 324.73M | 324.04M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |